167 results on '"Malander, Susanne"'
Search Results
2. High density of stroma-localized CD11c-positive macrophages is associated with longer overall survival in high-grade serous ovarian cancer
3. Incidence and survival of epithelial ovarian, fallopian tube, peritoneal, and undesignated abdominal/pelvic cancers in Sweden 1960–2014: A population-based cohort study
4. PD-1/PD-L1 expression and tumor-infiltrating lymphocytes are prognostically favorable in advanced high-grade serous ovarian carcinoma
5. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial
6. A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24
7. Tru-Cut Biopsy in Gynecological Cancer: Adequacy, Accuracy, Safety and Clinical Applicability
8. Age and Referral Route Impact the Access to Diagnosis for Women with Advanced Ovarian Cancer
9. Tru-Cut Biopsy in Gynecological Cancer: Adequacy, Accuracy, Safety and Clinical Applicability
10. Age and Referral Route Impact the Access to Diagnosis for Women with Advanced Ovarian Cancer
11. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial
12. Detecting TP53 mutations in diagnostic and archival liquid-based Pap samples from ovarian cancer patients using an ultra-sensitive ddPCR method
13. 2022-RA-245-ESGO Ovarian tumor frozen section, a multidisciplinary affair
14. 2022-RA-244-ESGO Prognostic value of peritoneal cancer index after complete cytoreductive suergery in advanced ovarian cancer
15. 2022-RA-1007-ESGO High expression of FAP+ cancer-associated fibroblasts predict poor outcome in patients with high-grade serous ovarian cancer with high CD8-postive T-cell infiltration
16. Claudin-4 Expression is Associated With Survival in Ovarian Cancer But Not With Chemotherapy Response
17. Ovarian tumor frozen section, a multidisciplinary affair
18. Copy number signatures for early diagnosis of high-grade serous ovarian carcinoma
19. Prognostic Value of Peritoneal Cancer Index After Complete Cytoreductive Surgery in Advanced Ovarian Cancer
20. Distinct gene expression profiles in ovarian cancer linked to Lynch syndrome
21. Ovarian tumor frozen section, a multidisciplinary affair
22. Ovarian cancer linked to lynch syndrome typically presents as early-onset, non-serous epithelial tumors
23. MET Expression and Cancer Stem Cell Networks Impact Outcome in High-Grade Serous Ovarian Cancer
24. The role of computed tomography in predicting peritoneal carcinomatosis and upfront surgery outcome in advanced ovarian cancer
25. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients
26. SOX2 is a promising predictor of relapse and death in advanced stage high-grade serous ovarian cancer patients with residual disease after debulking surgery
27. Final survival analysis of NSGO-AVANOVA2/ENGOT-OV24: Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer—A randomized controlled chemotherapy-free study.
28. Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial
29. Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer: A randomized controlled chemotherapy-free study-NSGO-AVANOVA2/ENGOT-OV24
30. Lactase persistence and ovarian carcinoma risk in Finland, Poland and Sweden
31. A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer:NSGO AVANOVA1/ENGOT-OV24
32. Pattern of endocrine treatment for epithelial ovarian cancer in the Southeast medical region of Sweden: a population-based study
33. Similarities and Differences of Blood N-Glycoproteins in Five Solid Carcinomas at Localized Clinical Stage Analyzed by SWATH-MS
34. A Targeted Mass Spectrometry Strategy for Developing Proteomic Biomarkers: A Case Study of Epithelial Ovarian Cancer
35. Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer: A randomized controlled chemotherapy-free study—NSGO-AVANOVA2/ENGOT-OV24.
36. Pattern of endocrine treatment for epithelial ovarian cancer in the Southeast medical region of Sweden: a population-based study
37. Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial
38. Involvement of Chromatin Remodeling Genes and the Rho GTPases RhoB and CDC42 in Ovarian Clear Cell Carcinoma
39. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
40. Involvement of Chromatin Remodeling Genes and the Rho GTPases RhoB and CDC42 in Ovarian Clear Cell Carcinoma
41. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): A randomised, double-blind, placebo-controlled phase 3 trial
42. Abstract 3348: Expression of putative cancer stem cell markers in fallopian tube epithelium from women at increased risk of developing high-grade serous ovarian cancer
43. Abstract B12: Targeted sequencing of ovarian clear cell carcinomas reveals intertumor heterogeneity and distinct clustering related to mutational load.
44. Sex Steroid Hormone Receptor Expression Affects Ovarian Cancer Survival.
45. Claudin-4 Expression is Associated With Survival in Ovarian Cancer But Not With Chemotherapy Response.
46. Sex Steroid Hormone Receptor Expression Affects Ovarian Cancer Survival
47. Abstract 1834: Sex hormone receptor expression affects ovarian cancer survival
48. Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO)
49. Molecular subtyping of serous ovarian tumors reveals multiple connections to intrinsic breast cancer subtypes.
50. Molecular Subtyping of Serous Ovarian Tumors Reveals Multiple Connections to Intrinsic Breast Cancer Subtypes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.